Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by Privium Fund Management B.V.

Privium Fund Management B.V. raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 14.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 380,586 shares of the biotechnology company's stock after buying an additional 47,230 shares during the period. Arrowhead Pharmaceuticals comprises about 1.6% of Privium Fund Management B.V.'s portfolio, making the stock its 15th largest holding. Privium Fund Management B.V. owned approximately 0.30% of Arrowhead Pharmaceuticals worth $7,155,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ARWR. World Investment Advisors LLC lifted its position in shares of Arrowhead Pharmaceuticals by 3.8% in the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company's stock valued at $371,000 after acquiring an additional 700 shares in the last quarter. Xponance Inc. lifted its holdings in Arrowhead Pharmaceuticals by 4.5% in the 4th quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company's stock valued at $327,000 after purchasing an additional 744 shares in the last quarter. Wellington Management Group LLP boosted its stake in Arrowhead Pharmaceuticals by 1.5% during the 3rd quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company's stock worth $1,199,000 after purchasing an additional 886 shares during the last quarter. Van ECK Associates Corp boosted its stake in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Arrowhead Pharmaceuticals by 5.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,262 shares of the biotechnology company's stock worth $586,000 after buying an additional 1,523 shares in the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Arrowhead Pharmaceuticals Stock Down 2.1 %

Shares of NASDAQ ARWR traded down $0.31 during mid-day trading on Friday, hitting $14.80. The company had a trading volume of 4,064,707 shares, compared to its average volume of 1,263,258. The company has a market capitalization of $2.03 billion, a PE ratio of -2.86 and a beta of 0.92. The business's 50-day simple moving average is $18.58 and its 200 day simple moving average is $19.90. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $14.23 and a 1-year high of $30.41. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 32,729 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $648,688.78. Following the completion of the sale, the insider now owns 272,122 shares in the company, valued at approximately $5,393,458.04. This represents a 10.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Patrick O'brien sold 29,184 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $578,426.88. Following the sale, the chief operating officer now directly owns 535,201 shares of the company's stock, valued at $10,607,683.82. The trade was a 5.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 301,730 shares of company stock worth $5,352,844 over the last ninety days. Corporate insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

ARWR has been the topic of several research reports. Piper Sandler decreased their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 27th. HC Wainwright reissued a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Chardan Capital restated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Citigroup reduced their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday, November 27th. Finally, Sanford C. Bernstein dropped their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating for the company in a report on Friday, November 29th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.